Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTerpath-004: V940 Plus Pembrolizumab in Adjuvant Renal Cell Carcinoma
NCT06307431Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2024
- Primary completion
- Jan 2028
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 14
01
Overview
A Phase 2 trial of intismeran autogene in renal cell carcinoma (RCC), sponsored by Merck & Co.. Started Apr 2024; status: active, not recruiting.
02
Drugs
intismeran autogene
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06307431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06307431.